Merck KGaA Moves to Secure a Polycythemia Vera siRNA Asset
Merck KGaA is paying $1.3 billion in cash to acquire Silence Therapeutics after mid-stage data for divesiran gave the British biotech a sharper clinical profile in polycythemia vera, a rare blood cancer marked by excessive red blood cell production. The deal values Silence at $20 per American depositary share, with each ADS representing three ordinary shares, and places a new owner behind one of the few siRNA programs with a clear hematology path into late-stage development.
The transaction is less about corporate expansion in the abstract than about a specific disease biology. Polycythemia vera is driven by overproduction of red cells, and divesiran was designed to silence TMPRSS6, a liver-expressed protein that helps regulate iron availability. By redirecting iron away from the bone marrow, the therapeutic strategy aims to slow erythropoiesis at its source rather than simply manage downstream consequences. In a disorder where iron handling and marrow output are tightly linked, that mechanism gives the program a coherent pharmacologic logic.
The central clinical signal arrived in August, when 88% of patients receiving divesiran in a phase 2 study met response criteria between Weeks 18 and 36. Response rates differed by schedule: 93.8% in the six-week dosing cohort and 81.3% in the 12-week cohort. Those numbers do not establish comparative efficacy with the rigor of a randomized head-to-head trial, but they do suggest that the molecule is engaging its target in a way that translated into measurable disease control across both regimens.
The dosing pattern may ultimately prove as important as the mechanism itself.
Weekly Injection Competition Pushes Divesiran Toward Longer-Interval Dosing
Silence is entering phase 3 with a practical argument: longer dosing intervals may matter in a chronic blood cancer where treatment burden affects adherence, persistence, and patient preference. Takeda and Protagonist’s Mimrylo, which reached FDA approval for polycythemia vera in August, was administered as a weekly self-injection in phase 3. Silence plans to test divesiran every 12 weeks in its own pivotal study, and that schedule could become a meaningful differentiator if efficacy holds and tolerability remains acceptable.
For patients living with a rare myeloproliferative neoplasm, dosing frequency is not a minor design feature. It shapes how often people need to self-inject, how much treatment intrudes on daily life, and how likely a therapy is to be sustained over years rather than months. A drug that preserves control while stretching visits or injections farther apart can alter the real-world experience of care, especially in chronic diseases where long-term adherence is as relevant as initial response.
Merck KGaA is buying into that proposition at an early but plausible stage. Silence has described the phase 2 readout as a springboard to phase 3, and the acquisition places the development program inside a larger organization with broader operational and commercial reach. In practical terms, the deal reduces the risk that a promising hematology asset stalls before the late-stage evidence needed for broader adoption.
A Rare Blood Cancer With a Targetable Iron Pathway
Polycythemia vera is a disease in which the marrow produces too many red blood cells, increasing blood viscosity and raising the risk of serious complications if the disorder is not controlled. Existing therapies often work by suppressing the marrow indirectly or by modulating iron homeostasis, and the arrival of another approach based on siRNA expands the field’s options without changing the underlying disease target: unchecked red cell production.
Divesiran’s design fits neatly into that framework. Silencing TMPRSS6 in liver cells alters iron regulation upstream, which in turn limits the substrate available for erythropoiesis. The concept is biologically elegant because it attacks a control point rather than chasing the consequences of overproduction after they appear in the bloodstream. If later-phase data confirm durable hematologic control, the program could sit alongside other iron-pathway therapies while offering a different dosing rhythm.
The broader value of the deal is also tied to how quickly the program has moved from biology to clinic. Silence’s phase 2 findings gave the company a credible late-stage argument, and Merck’s acquisition gives that argument a stronger financial and organizational backstop. This is the kind of asset sale that often follows a clean mid-stage signal: the data are not definitive, but they are strong enough to attract a buyer willing to finance the next proof point.
Merck’s Portfolio Shift Toward Specialized and Rare Disease Programs
The acquisition also reflects Merck KGaA’s continuing push into targeted specialty and rare disease assets. Chief executive Kai Beckmann framed the purchase as part of the company’s strategic priority to pursue attractive end markets through M&A and to create value over the mid- to long-term. He also linked the move to Merck’s ongoing effort to reshape its pipeline toward higher-specialization areas with unmet medical need.
That corporate logic has been visible before. Merck acquired SpringWorks Therapeutics last year, and the Silence purchase extends the same pattern: buy programs with clearer specialty-disease positioning, then use scale to carry them deeper into development. The scientific rationale matters because these are not broad primary-care franchises; they are concentrated bets on defined mechanisms, defined populations, and high-value clinical endpoints.
Silence’s remaining pipeline adds context, but the acquisition hinges overwhelmingly on divesiran. The company’s other clinical asset, zerlasiran, is aimed at atherosclerotic cardiovascular disease through LPA silencing, while SLN312 targets ANGPTL3 for dyslipidemia. Neither program has the same immediate clinical traction as divesiran in polycythemia vera, and both have faced development setbacks or uncertainty. The deal therefore reads less like a wide portfolio sweep than a focused purchase of the one asset with the strongest current momentum.
What the Phase 3 Readout Will Need to Prove
The next test is straightforward but unforgiving: whether the phase 2 response can be reproduced in a larger trial designed to withstand regulatory scrutiny. The six-week and 12-week cohorts already suggest that schedule may influence response depth or durability, yet the current data set is too small to settle that question. A phase 3 program will need to clarify whether the longer interval preserves efficacy, whether the response remains durable over time, and how the safety profile compares with established options.
Merck has bought a clinical hypothesis with a live late-stage plan attached to it. The real judgment will come when that hypothesis is measured against a larger polycythemia vera population, where the durability of red cell control, the burden of injections, and the practical trade-offs of chronic treatment will determine whether divesiran becomes more than an acquisition story.